Cite
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
MLA
Mc Causland, Finnian R., et al. “Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.” American Journal of Nephrology, vol. 46, no. 6, Jan. 2018, pp. 488–97. EBSCOhost, https://doi.org/10.1159/000485326.
APA
Mc Causland, F. R., Claggett, B., Pfeffer, M. A., Burdmann, E. A., Eckardt, K.-U., Levey, A. S., McMurray, J. J. V., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R. D., & Parfrey, P. (2018). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American Journal of Nephrology, 46(6), 488–497. https://doi.org/10.1159/000485326
Chicago
Mc Causland, Finnian R., Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai-Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, et al. 2018. “Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.” American Journal of Nephrology 46 (6): 488–97. doi:10.1159/000485326.